Based on recent data, LB Pharmaceuticals Inc Common Stock (LBRX) shows an Average True Range (ATR) of 1.48 and an Enterprise Value of N/A. Its average trading volume over the past 3 months is 263.56K, indicating liquidity. These fundamental metrics provide insight into LBRX's underlying financial health and market activity.
| ATR | 1.48 |
| Enterprise Value | - |
| Avg Vol (3 Months) | 263.56K |
| Avg Vol (10 Days) | 318.88K |
LB Pharmaceuticals Inc Common Stock (LBRX) technical indicators as of July 9, 2026: the SMA 20 is 3.02%, SMA 50 at 9.82%, and SMA 200 at 28.32%. The RSI 14 value is 56.06, suggesting its current momentum. These technical analysis signals help assess LBRX's price trends and potential future movements.
| SMA 20 | 3.02% |
| SMA 50 | 9.82% |
| SMA 200 | 28.32% |
| RSI 14 | 56.06 |
LB Pharmaceuticals Inc Common Stock (LBRX) stock performance overview as of July 9, 2026: The 52-week high is N/A (currently -5.35% below), and the 52-week low is N/A (currently 81.36% above). Over the past year, LBRX's performance is N/A, compared to the S&P 500's 5.45% change.
| 52-Week High | N/A |
| 52-Week High Chg | -5.35% |
| 52-Week Low | N/A |
| 52-Week Low Chg | +81.36% |
| S&P 500 52-Week Chg | 5.45% |
According to current financial data, LBRX stock's P/E (TTM) ratio is -1.56, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.22. Key valuation ratios for LBRX, including P/S (N/A), P/B (2.49), and P/FCF (-19.01), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | LBRX | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | -1.56 | -1.22 | -194.02 | 32.59 |
| P/S (TTM) | N/A | 3.68 | 466.98 | 5.98 |
| P/B (TTM) | 2.49 | 0.06 | 11.22 | 5.25 |
| P/FCF (TTM) | -19.01 | -24.92 | -613.7 | 29.69 |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep